Associate Professor, Weill Cornell Medical College, Leader Early Drug Development in Hematology, Houston Methodist
Hematology
Dr. Swaminathan P. Iyer, MD
|
|
Give Review
Swaminathan P. Iyer, MD practices Hematology. He researched medicine at Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. He received 17 awards: "President", "Virginia and Ernest Cockrell Presidential Award", "Young Investigator Award", "ACS Institutional Grant", "Outstanding Physician Volunteer", "LLS SCORE Subaward", "Outstanding Volunteer Physician for 2010", "Best Teacher Award", "Whos Who in Healthcare", "Americas Top Physicians", "Merit Award", "Gold Medal for highest score in Pathology", "Third in State Level Psychiatry Quiz", "University champion in Pediatric Quiz", "Certificates of Merit", "Medal for 7th rank in country for National Talents Search Exam" and "Virginia &Cockrell Jr.Scholar". Swaminathan Iyer has written publications. He has 58 publications published with PubMed. The lastest publication is: 'Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia.'
Publications
- Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia.
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAU...
- A unique aptamer-drug conjugate for targeted therapy of multiple myeloma.
- Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.
- HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
- Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
- Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refr...
- Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple my...
- Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD.
- A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple...
- Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells.
- WTAP is a novel oncogenic protein in acute myeloid leukemia.
- Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
- Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
- Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
- The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor α-related ...
- Bridging the gap in hematological malignancies.
- Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
- Targeting aurora kinases in cancer treatment.
- Targeting PIM kinase activity significantly augments the efficacy of cytarabine.
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study.
- A comparison of races and leukemia subtypes among patients in different cancer survivorship phases.
- A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy.
- Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia.
- Mammalian target of rapamycin as a target in hematological malignancies.
- Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
- Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
- Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
- Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
- Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
- Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refrac...
- Seeing what's out of sight: wireless capsule endoscopy's unique ability to visualize and accurately assess the severity of gastrointestinal graft-versus-host-disease.
- Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
- Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies.
- Current status of therapy for chronic myeloid leukemia: a review of drug development.
- Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed ...
- High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
- HLA-identical sibling stem-cell transplantation in first-remission AML.
- Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.
- Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage.
- Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
- Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.
- Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels.
- Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incid...
- Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation.
- Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature.
- Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression.
- Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
- Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung c...
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- President
- Virginia and Ernest Cockrell Presidential Award
- Young Investigator Award
- ACS Institutional Grant
- Outstanding Physician Volunteer
- LLS SCORE Subaward
- Outstanding Volunteer Physician for 2010
- Best Teacher Award
- Who’s Who in Healthcare
- America’s Top Physicians
- Merit Award
- Gold Medal for highest score in Pathology
- Third in State Level Psychiatry Quiz
- University champion in Pediatric Quiz
- Certificates of Merit
- Medal for 7th rank in country for National Talents Search Exam
- Virginia &Cockrell Jr.Scholar
Education
-
Jackson Memorial Hospital - Jackson Health System -
Wayne State University School of Medicine -
Bangalore Medical College
Hospital
-
Baylor St. Luke's Medical Center
Drug Facts
| NPI NUMBER | 1063493229 | |
| NPPES Provider LastName | IYER | |
| NPPES Provider FirstName | SWAMINATHAN | |
| NPPES Provider ZIPCode | 770301502 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 428.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 28.0 | |
| Percent Opioid Claims | 6.54 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063493229 |
| Last Name Of The Provider | IYER |
| First Name Of The Provider | SWAMINATHAN |
| View All |
Similar Doctors
|
|
Dr. Jean-Pierre Ayoub, MD |
|
|
Dr. Cristina Rodriguez, MD |
|
|
Dr. Richard E. Champlin, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michelle A. Fanale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna Przepiorka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jianjun Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Milind Javle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yanyan Lou, MD |
|
|
Dr. Mahesh Kanojia, MD |
|
|
Dr. Aditi Shastri, MD
This Doctor is OpenDoctor Recommended.
|